PEPFAR had been set to lead the rollout of Gilead Science's lenacapavir, which has been hailed as a "miracle" of HIV ...

Tomas Cihlar knew all too well that despite initial successes with combination treatment, HIV was firmly holding ground ...

Gilead Sciences (GILD) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some ...

News of potential federal budget cuts impacting HIV drugs in the U.S. was quickly reflected in a dip in share prices for top ...

The Health and Human Services Department is considering cuts to HIV prevention funding, according to The Wall Street Journal.

On the same day the Trump Administration unceremoniously shut down the U.S. Department of Health and Human Services Regional Office in San Francisco, a major HIV drug maker ...

HIV infection and lung cancer have little in common from a disease perspective, but the stigma that surrounds both can ...

Gilead Sciences has been one of the best-performing large biotech companies over the past year, rising about 50%. That is ...

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Gilead Sciences (GILD) ended the recent trading session at $111.88, demonstrating a +0.54% swing from the preceding day's closing price. The stock fell short of the S&P 500, which registered a gain of ...

Gilead Sciences Inc. CEO Daniel O'Day's compensation rose 4.8% last year to $23.7 million — roughly $97 for every buck made ...

March 12, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of late-breaking data and multiple oral presentations from its innovative HIV treatment portfolio and pipeline ...